BERWYN, Pa.–(BUSINESS WIRE)–#pharma—Virpax® Pharmaceuticals, Inc. (“Virpax”) (NASDAQ: VRPX), a company specializing in product candidates for pain management, CNS disorders and anti-viral indications, today announced that it will be presenting virtually at the upcoming H.C. Wainwright event from Tuesday, May 24th starting at 7:00 a.m. ET through Friday, May 27th. Anthony P. Mack, Chairman & CEO of … [Read more…]
-Expanded clinical development presence is expected to accelerate activities for THIO-101 Phase 2 Trial for NSCLC- CHICAGO–(BUSINESS WIRE)–MAIA Biotechnology, Inc., a targeted therapy, immuno-oncology company focused on developing potential first-in-class oncology drugs (“MAIA”), announced today that the company has established two wholly-owned subsidiaries in Romania and Australia to broaden and accelerate its global development plan … [Read more…]
The appointment will support Biognosys’ transformation to a leading provider of protein insights for the development of new breakthrough treatments ZURICH–(BUSINESS WIRE)–#ClinicalResearch–Biognosys, a leader in next-generation proteomics solutions for life science research and drug development, announced today the appointment of Beat Lüthi, Ph.D., as Board Director. Dr. Lüthi is Chief Executive Officer of CTC Analytics … [Read more…]
– Data show that combination of two antibodies in Immunome’s cocktail successfully neutralized the Omicron variant in vivo in hamsters – – IMM20253 antibody also retained activity against BA.2 subvariant in pseudovirus testing in vitro, with additional testing underway – EXTON, Pa.–(BUSINESS WIRE)–Immunome, Inc. (Nasdaq: IMNM), a biopharmaceutical company that utilizes its human memory B … [Read more…]
ENGLEWOOD, Colo.–(BUSINESS WIRE)–Paragon 28, Inc. (NYSE: FNA), a leading medical device company exclusively focused on the foot and ankle orthopedic market, today announced further expansion of its hammertoe and soft-tissue portfolio with the launch of its TenoTac™ 2.0 Soft Tissue Fixation System. The TenoTac™ 2.0 Soft Tissue Fixation System uses a titanium threaded implant and … [Read more…]
New post-hoc data accepted as late breaking abstracts at the 90th European Atherosclerosis Society (EAS) Congress and 2022 National Lipid Association (NLA) Scientific Sessions NAARDEN, Netherlands & MIAMI–(BUSINESS WIRE)–NewAmsterdam Pharma (NewAmsterdam), a clinical-stage company focused on the research and development of transformative oral therapies for metabolic diseases, today announced that it will present new post-hoc … [Read more…]
BOSTON–(BUSINESS WIRE)–Pear Therapeutics, Inc. (Nasdaq: PEAR), the leader in developing and commercializing software-based medicines called prescription digital therapeutics (PDTs), today announced that it will host an inaugural virtual Investor Day on June 6, 2022, at 10:00 a.m. – 12:30 p.m. ET. Pear’s Investor Day will feature presentations by members of the management team. The company … [Read more…]
NEW YORK–(BUSINESS WIRE)–$SDGR—Schrödinger, Inc. (Nasdaq: SDGR), whose physics-based software platform is transforming the way therapeutics and materials are discovered, today announced the appointment of Arun Oberoi to its Board of Directors, effective May 17, 2022. Mr. Oberoi will serve as a member of the Audit Committee. “We are very pleased to welcome Arun to our … [Read more…]
LITTLETON, Mass.–(BUSINESS WIRE)–#ProtonTherapy—Mevion Medical Systems announced today that it has been selected to install a MEVION S250i Proton Therapy System® with HYPERSCAN® Pencil Beam Scanning (PBS) in a comprehensive hospital in Southern China. Proton therapy is a superior form of radiation therapy that can reduce the amount of unnecessary radiation exposure to surrounding healthy tissue … [Read more…]
FRIENDSWOOD, Texas–(BUSINESS WIRE)–$CSTL #CSTL–Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced new data showing that DecisionDx-SCC can independently risk-stratify patients with cutaneous squamous cell carcinoma (SCC) and one or more risk factors according to their biologic risk of metastasis, consistent with findings in previous development … [Read more…]
